Phase II Trial of Apatinib in Patients with Recurrent And/or Metastatic Adenoid Cystic Carcinoma of the Head and Neck: Updated Analysis.

Guopei Zhu,Lin Zhang,Rongrong Li,Shengjin Dou,Wenjun Yang,Chenping Zhang

DOI: https://doi.org/10.1200/jco.2018.36.15_suppl.6026

IF: 45.3

2018-01-01

Journal of Clinical Oncology

Abstract:6026 Background: There is no specific therapy, including targeted agents, has consistently improved clinical outcomes in recurrent/metastatic adenoid cystic carcinoma of the head and neck (ACCHN). Recently, anti-angiogenic targeted therapy represents a potential effective strategy. We conducted a single-arm, phase II trial to evaluate apatinib, a small-molecule inhibitor of VEGFR-2, in ACCHN, and promising response was observed (2018 Multidisciplinary Head and Neck Cancers Symposium Abstract: 20160). Here we report the updated efficacy and safety data. Methods: Pathologically confirmed recurrent and/or metastatic ACCHN patients (pts) who had evidence of disease progression within 3 months or had failed at least 1 line of systemic chemotherapy were eligible. All pts received continuous apatinib 500 mg qd until disease progression, death, or intolerable toxicity. Results: Between Apr 2016 and Dec 2017, 59 pts were recruited, including 22 (37.3%) males and 37 (62.7%) females. The median age was 47.5 years. 61.0% cases had metastases, and the main metastatic site was lung. All pts were evaluable for efficacy and safety analyses. At the cutoff date of 12/31/2017, 9 progression-free survival (PFS) events and 2 deaths after progression occurred. The median PFS and overall survival (OS) had not been reached; however, the median time of apatinib treatment was already 6.4 (IQR, 3.8–9.9) months. The 6-month PFS rate was 87.9% (95%CI, 76.6%–99.1%), and the 12-month PFS rate was 50.7% (95%CI 21.8%–79.7%). The 12-month OS rate was 96.3% (95%CI, 91.3%–101.3%). Moreover, the objective response rate and disease control rate was 47.1% and 98.1%, respectively. 34 (57.6%) pts experienced dose reduction. The incidence of drug-related adverse events (AEs) was 88.1% (52/59). 22.0% (13/59) pts developed AEs of Grade ≥3. Main AEs were hypertension (54.2%), hand-foot syndrome (33.9%), and proteinuria (23.7%). Conclusions: This updated analysis further confirmed that apatinib appears to be effective and safe for recurrent/metastatic ACCHN. It did achieve the best reported response rate and long duration of disease control with a good safety profile. Further investigation is warranted. Clinical trial information: NCT02775370.